AbbVie bets $370M on pivotal eye disease gene therapy, puts up $1.4B in biobucks Everest bags COVID-19 program in bid to conquer Chinese mRNA market Where are they now? Tracking down 2011’s Fierce 15 Sponsored: Four Steps to Smarter, More Dynamic Deployment AzurRx boosts GI pipeline through First Wave buyout worth up to $229M Bellus offers a scrap of analysis for chronic cough candidate in first-to-market battle with Merck Provention will wait for FDA to 'opine' on new data after teplizumab rejection, eyes Q4 for further talks 4 years after leaving Prime time, Rusty Williams lands a new job leading school of Walking Fish OrbiMed, Lilly Asia Ventures chip into ADARx's $75M round to take RNA tech into the clinic AltruBio snags a CMO after pivot from oncology to immunology The top 10 antibody drug conjugate contenders in 2021 AI drug hunter Exscientia plans to go public with Nasdaq IPO Departing FDA officials say it's too soon for COVID-19 boosters as White House plans rollout next week Featured Story | By Nick Paul Taylor AbbVie is betting $370 million on gene therapy. Having dipped its toe into the sector through other deals, AbbVie is now immersing itself through a deal with Regenxbio for eye disease gene therapy RGX-314. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The Chinese mRNA sector is heating up. In the wake of megarounds by its compatriots, Everest Medicines has bought its way into the mRNA COVID-19 vaccine space through a deal with Providence Therapeutics. read more By Annalee Armstrong While the Fierce Biotech team evaluates the most innovative biotechs worthy of the 2021 Fierce 15, it’s time to check in with the class of 2011. read more Sponsored by: IQVIA Are you using data and analytics to design smarter campaigns and more effective sales rep deployment? read more By Amirah Al Idrus AzurRx is bolstering its pipeline and assuming a new name through its acquisition of First Wave Bio. The cash-and-stock deal could be worth up to $229 million and includes future payments if development, regulatory and sales goals are met. read more By Annalee Armstrong Bellus Health needed a win for its chronic cough medicine BLU-5937 after dropping a previous round to Merck, and a new, planned interim analysis seems to have given the company what it needs to plan for phase 3. read more By Ben Adams Provention Bio is being optimistic about the chances of resubmitting the rejected Type 1 diabetes asset teplizumab after the biotech's shares took a battering on the FDA’s recent complete response letter. After scraping through a tough advisory committee in March, the FDA returned a no verdict for approval of the therapy in July. read more By Ben Adams Hoping to evolve new treatments across the board using B-cell therapies, Walking Fish Therapeutics has nabbed $50 million and a new chief in the form of an industry veteran. read more By Emmy Lucas OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals’ $75 million series B round. The funding will take the San Diego-based biotech’s growing pipeline of RNA-targeting therapeutics into the clinic, ADARx said in a statement on Wednesday. read more By Amirah Al Idrus AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board. Jesse Hall, M.D., arrives from Sublimity Therapeutics, where he led clinical development for inflammatory bowel disease programs as its chief medical officer. read more By Arlene Weintraub After decades of trial and error, the development of antibody drug conjugates (ADCs) is poised for a renaissance. Here are our top picks. read more By Conor Hale The U.K.-based AI developer confidentially filed for a $100 million IPO in late June, though the pricing terms could climb higher. read more By Noah Higgins-Dunn Even with the wave of delta variant-driven COVID-19 cases in the U.S., the authorized vaccines appear to be staving off severe infections. Boosters for the general population are not needed at this time, leading scientists with the FDA and the World Health Organization argued in a paper on Monday. read more | | The life-changing potential of cell & gene therapy demands lab services that are just as transformative. LabConnect® leads the evolution of lab services with customized solutions that simplify clinical trial complexity. Let us help with your next study so you can focus on the research. Learn more. |
Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Medical Affairs Strategic Summit (MASS) September 13-15, 2021 | New Brunswick, NJ Let A Digital Sherpa Uncomplicate The Path for Patients Wednesday, September 15 | 1 PM ET Sea-dumped chemical weapons: environmental risk, occupational hazard September 22, 2021 1pm EST Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA The MedTech Conference 2021 September 27 - 30, 2021 Introduction to Structure Elucidation in Drug Development Sep 29, 2021 1 pm EST Pharma PR & Communications Summit October 4-5, 2021 | Jersey City, NJ Virtual U.S. Healthcare Compliance Certificate Program October 11 – 14, 2021 Fierce Biotech Cell & Gene Therapy October 19, 2021 | Virtual Event Fierce Health Payer Summit October 26, 2021 | Virtual Event Diversity, Equity & Inclusion Week November 9–11, 2021 | Virtual Event Announcing the 9th International mRNA Health Conference November 09-10, 2021 | Mercure MOA Berlin & Online Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Fierce Biotech Forum 2022 | Virtual Event | 